Patient handout

Atypical / scar-mediated / left atrial flutter

PRODUCTION

1. Your condition

This handout is for atypical / scar-mediated / left atrial flutter. Your care team identified this based on: flutter waves not meeting typical cti criteria — positive in ii/iii/avf, prominent v1, variable axis.

Other reasons your team may use this plan: recurrent atrial flutter after prior af ablation (pvi), maze, cabg, valve, or transplant — scar-mediated reentry; palpitations / dyspnea / fatigue in patient with prior left atrial intervention or congenital heart disease.

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
metoprolol_tartrate	5 mg IV q5min × 3 then 25–50 mg PO BID	IV/PO	IV q5min × 3 → PO BID	AVN slowing for atypical flutter (often refractory) — ACC/AHA 2024 (PMID 38753446)
amiodarone	150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance	IV/PO	load + daily	Most efficacious AAD for atypical/scar-mediated flutter; preferred over class IC (CAST PMID 1900101) given structural HD; pulm/thyroid/hepatic toxicity — ACC/AHA 2024 (PMID 38753446)
dofetilide	125–500 mcg PO BID per CrCl (REMS — inpatient initiation)	PO	BID	Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
apixaban	5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5)	PO	BID	AC same as AF; lifelong AC typical given high mixed AF/AFL coexistence — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
rivaroxaban	20 mg with food (15 mg if CrCl 15–50)	PO	once daily	X-VeRT (PMID 24837375); ROCKET-AF foundational
warfarin	INR 2–3	PO	daily	Mechanical valve / severe MS — only warfarin (common in post-valve atypical flutter) — ACC/AHA 2024

Plan: Atypical / scar-mediated / left atrial flutter — rate control + AAD (often refractory) + AC + 3D electroanatomic mapping ablation pathway — ACC/AHA 2024 (Joglar PMID 38753446); Aliot 2009 (PMID 19324313)

3. When to call your provider

Contact your care team if any of the following happen:

Recurrent atypical flutter despite ablation → repeat 3D EP mapping (Aliot 2009)
New AF detected → AF management via cardio.afib.core.v1; consider PVI
Amiodarone toxicity (pulm fibrosis, thyroid, LFT) → switch to dofetilide or repeat ablation — ACC/AHA 2024
Stroke / TIA on AC → workup + reassess regimen — ACC/AHA 2024

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

Atypical flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 100–200 J biphasic now (atypical often needs higher energy than typical CTI)(life-threatening)
Recurrent scar-mediated atrial tachycardia within 3 months of LA ablation — common given complex circuits
Periprocedural AC management for LA ablation — continuation vs hold of DOAC, heparin bridge timing, post-procedure resumption window
Fever + chest pain + new neurologic deficit 2–6 weeks post-LA ablation → emergency surgical evaluation; HIGHER RISK in LA ablation than CTI(life-threatening)
New pulmonary infiltrates, thyroid dysfunction (hypo or hyper), or LFT elevation on amiodarone — switch AAD or accept AAD failure → re-ablation

5. Follow-up

EP for 3D mapping ablation; cardiology q3–6 mo; AC continuation per CHA2DS2-VASc (lifelong given mixed AF/AFL); lifestyle (alcohol, weight, OSA); post-ablation 4-week ECG + Holter at 3/6/12 mo for AF screen

6. Sources

Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); ESC 2024 AF (Van Gelder EHJ 2024 PMID 39050851); HRS/EHRA/ECAS 2007 catheter ablation expert consensus (Calkins PMID 17572388); Aliot 2009 ESC EP/HRS expert consensus on VT/AT ablation (PMID 19324313)